Same medicine. Same results.
Lower cost.
  • Biosimilars

    Biosimilars

    GPhA applauds Congress for establishing an abbreviated...
  • Drug Shortages

    As members of the public who also are affected by...
  • Quality

    Science and quality are the cornerstones of the generic...
  • Patent Settlements

    Patent Settlements

    GPhA vigorously opposes restricting the right of parties in...
  • GDUFA

    GPhA and its member companies support full implementation...
 
 

Improving Lives for Less

*New data* The 2016 Generic Drug Savings and Access in the U.S. report shows that generic pharmaceuticals saved the U.S. health system $227 billion in 2015. This year’s report features state-by-state savings, therapy area and public program savings and more. Data compiled by the QuintilesIMS Institute. Learn more >



Value and Quality

The Biosimilars Council

The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines.

Click here for more information.



ACCESS! 2017

Epic Challenges. Epic Opportunities.

Are you ready to aspire to new levels of excellence in life and business? Join us at #ACCESS17, the GPhA Annual Meeting where nearly 700 attendees gather to gain insight on how the nation's most critical health and regulatory issues will impact the generic industry and the consumers who benefit from access to affordable medicines. Featuring kenote speaker Captain “Sully” SullenbergerRegister now >